KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Cash from Investing Activities (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Cash from Investing Activities for 18 consecutive years, with -$428.9 million as the latest value for Q1 2026.

  • For Q1 2026, Cash from Investing Activities fell 166.24% year-over-year to -$428.9 million; the TTM value through Mar 2026 reached -$1.7 billion, down 1177.53%, while the annual FY2025 figure was -$629.1 million, 74.51% up from the prior year.
  • Cash from Investing Activities hit -$428.9 million in Q1 2026 for Regeneron Pharmaceuticals, down from $220.3 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $647.5 million in Q1 2025 and bottomed at -$2.4 billion in Q2 2023.
  • Average Cash from Investing Activities over 5 years is -$617.4 million, with a median of -$428.9 million recorded in 2026.
  • On a YoY basis, Cash from Investing Activities climbed as much as 629.61% in 2024 and fell as far as 615.78% in 2024.
  • Regeneron Pharmaceuticals' Cash from Investing Activities stood at -$1.9 billion in 2022, then soared by 96.44% to -$66.2 million in 2023, then surged by 629.61% to $350.6 million in 2024, then crashed by 37.16% to $220.3 million in 2025, then crashed by 294.69% to -$428.9 million in 2026.
  • According to Business Quant data, Cash from Investing Activities over the past three periods came in at -$428.9 million, $220.3 million, and -$402.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.